![Pooled analysis questions reliability of an endpoint used in multi-cancer detection trials](https://cdn.cancerletter.com/media/2024/04/12143517/50-15-4x3-1.jpg)
![Pooled analysis questions reliability of an endpoint used in multi-cancer detection trials](https://cdn.cancerletter.com/media/2024/04/12143517/50-15-4x3-1.jpg)
Cover Story
Clinical
An analysis by researchers from the International Agency for Research on Cancer casts doubt on validity of an endpoint used in key studies of multi-cancer detection tests.
In Brief
![In Brief](https://cdn.cancerletter.com/media/2019/05/03155624/in-brief-3.jpg)
![In Brief](https://cdn.cancerletter.com/media/2019/05/03155624/in-brief-3.jpg)
Funding Opportunities
Clinical Roundup
![Clinical Roundup](https://cdn.cancerletter.com/media/2019/05/03161627/clinical_roundup.jpg)
![Clinical Roundup](https://cdn.cancerletter.com/media/2019/05/03161627/clinical_roundup.jpg)
Drugs & Targets
Trending Stories
- When tobacco companies sponsored the Olympics
- U.S. News rankings for cancer hospitals shift again with inclusion of Medicare Advantage data
Rankings now include a list of Best Regional Hospitals for Equitable Access - How Beth Carner went from six weeks left to live with stage 4 colon cancer to complete remission
- Kamala Harris widely expected to continue Cancer Moonshot; Conservatives present their vision in Project 2025
- Cancer Moonshot contributes additional $100M to reduce cancer burden in Africa
- Robert Gallo named founding director of Microbial Oncology Program at TGH Cancer Institute